Underweight in Type 2 Diabetes Raises Cardiovascular Risk — Severe Leanness Carries Greater Risk Than Obesity
Posted inCardiology Diabetes & Endocrinology news

Underweight in Type 2 Diabetes Raises Cardiovascular Risk — Severe Leanness Carries Greater Risk Than Obesity

A nationwide Korean cohort found that underweight patients with Type 2 diabetes—especially those with severe underweight—have higher cardiovascular risk than normal-weight and even some obese patients, underscoring the need to screen and manage malnutrition, sarcopenia, and frailty in diabetes care.
SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts
Posted inDiabetes & Endocrinology Gastroenterology news

SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts

A multicenter target‑trial emulation found SGLT2 inhibitor initiation was associated with a 22% lower risk of progression to advanced fibrosis (confirmed FIB‑4 >2.67) versus DPP‑4 inhibitors in adults with MASLD and T2DM and low‑to‑intermediate baseline fibrosis.
GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study
Posted inCardiology Diabetes & Endocrinology news

GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study

In a 241,981-patient emulated trial using modern causal methods, sustained GLP‑1RA use yielded the lowest 2.5‑year MACE risk, followed by SGLT2is, sulfonylureas, and DPP4is; the GLP‑1RA advantage over SGLT2is was greatest in older adults and those with ASCVD, HF, or kidney impairment.
Baseline SGLT2 Inhibitor Use Associated with Lower Risk of Sepsis-Induced Cardiomyopathy and Improved Outcomes in Type 2 Diabetes: Insights from a Large Propensity-Matched Cohort
Posted inCardiology Critical Care news

Baseline SGLT2 Inhibitor Use Associated with Lower Risk of Sepsis-Induced Cardiomyopathy and Improved Outcomes in Type 2 Diabetes: Insights from a Large Propensity-Matched Cohort

A large propensity-matched cohort study found that baseline SGLT2 inhibitor use versus DPP4 inhibitor therapy in adults with type 2 diabetes and infection was associated with lower 30-day sepsis-induced cardiomyopathy and improved 1-year mortality and cardiovascular outcomes; residual confounding and safety considerations warrant prospective trials.
SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection
Posted inDiabetes & Endocrinology Neurology news

SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection

A 20‑year TriNetX analysis of 913,428 T2DM patients found SGLT2 inhibitor use associated with a 28% lower Parkinson’s disease risk versus metformin (aHR 0.72), suggesting possible superior neuroprotection and prompting need for prospective confirmation.
SGLT-2 Inhibitors and Autoimmune Rheumatic Disease Risk Reduction in Type 2 Diabetes: Insights from a Korean Nationwide Cohort
Posted inDiabetes & Endocrinology news Rheumatology

SGLT-2 Inhibitors and Autoimmune Rheumatic Disease Risk Reduction in Type 2 Diabetes: Insights from a Korean Nationwide Cohort

A large South Korean cohort study suggests that sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce the incidence of autoimmune rheumatic diseases by 11% compared to sulfonylureas in adults with type 2 diabetes, indicating potential immunomodulatory benefits of SGLT-2 inhibitors beyond glycemic control.
Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review
Posted inDiabetes & Endocrinology Gastroenterology news

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review

This systematic review evaluates the effects of specific plant-based foods on metabolic and hepatic outcomes in adults with MASLD and related comorbidities. Findings reveal selective benefits of plant-based dietary components on liver health, glycemic control, and lipid profiles, underscoring potential dietary strategies for MASLD management.